Get notified when AVXL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Governance misconduct
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Departure Of Ceo (new) — The CEO was terminated for cause by a special committee of independent directors for conduct inconsistent with company policy.
Anavex terminates CEO Christopher Missling for cause, names Terrie Kellmeyer Interim CEO
Filed May 6, 2026 · Period ending April 30, 2026 · ~1 min read
Key Changes
-
high
CEO Christopher Missling was terminated for cause on April 30, 2026, by a special committee of independent directors for conduct inconsistent with company policy. The committee has requested his resignation from the Board.
Item 5.02 verify on EDGAR → -
high
Terrie Kellmeyer, PhD, appointed Interim CEO on May 4, 2026. She brings 30+ years of pharma experience and previously served as the company's SVP of Clinical Development from November 2023 to May 2025.
Item 5.02 verify on EDGAR → -
medium
Kellmeyer's compensation includes $500K base salary, 30% target bonus, $150K signing bonus, and 200,000 stock options to be granted shortly after her start date.
Item 5.02 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade AVXL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify